Sitagliptin improves plasma apolipoprotein profile in type 2 diabetes: A randomized clinical trial of sitagliptin effect on lipid and glucose metabolism (SLIM) study
| Autor: | Mototsugu Nagao, Hitoshi Sugihara, Suminori Kono, Slim Study Investigators, Shinichi Oikawa, Shigeki Moritani, Taro Harada, Jun Sasaki, Kyoko Tanimura-Inagaki |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Apolipoprotein B Endocrinology Diabetes and Metabolism Type 2 diabetes chemistry.chemical_compound Endocrinology Diabetes mellitus Internal medicine Internal Medicine medicine Humans Hypoglycemic Agents Dipeptidyl-Peptidase IV Inhibitors biology Cholesterol business.industry Sitagliptin Phosphate nutritional and metabolic diseases Type 2 Diabetes Mellitus Lipid metabolism General Medicine Middle Aged medicine.disease Lipids Apolipoproteins Glucose Sulfonylurea Compounds chemistry Diabetes Mellitus Type 2 Sitagliptin biology.protein lipids (amino acids peptides and proteins) Female business Chylomicron medicine.drug |
| Zdroj: | Diabetes research and clinical practice. 162 |
| ISSN: | 1872-8227 |
| Popis: | Aim This study aims to evaluate the effect of dipeptidyl peptidase-4 inhibitors on lipid metabolism in patients with type 2 diabetes mellitus (T2D). Methods This is a multicenter, open-labeled, randomized controlled study. T2D patients with HbA1c 6.9–8.9% (52–74 mmol/mol) who were under treatment with sulfonylurea were randomly allocated to either the sitagliptin group or the non-sitagliptin group. Glucose and lipid metabolism parameters including apolipoproteins (apo), sterols, and urinary albumin were assessed at baseline, 3, and 6 months of the treatment. Results A total of 164 patients completed the 6-month observation (n = 81 for sitagliptin and n = 83 for non-sitagliptin). HbA1c decreased in the sitagliptin group but not in the non-sitagliptin group. Serum TG and total, LDL and HDL cholesterol levels did not change in either group. Apo B-48, apo CII, and apo CIII levels decreased in the sitagliptin group, but not in the non-sitagliptin group. The change in urinary albumin was significantly different between the groups with a preferable change in the sitagliptin group. There were no changes in serum sterols levels in the two groups. Conclusions The treatment of sitagliptin for 6 months improves the metabolism of glucose and chylomicron and reduces plasma levels of atherogenic lipoproteins in patients with T2D. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect